Biote financials
$1.24+0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $192.2M | $197.2M | $185.4M | $165.0M |
| Gross profit | $137.4M | $139.1M | $127.5M | $110.4M |
| Gross margin | 71.5% | 70.5% | 68.8% | 66.9% |
| Operating income | $35.6M | $31.6M | $28.7M | -$60.7M |
| Net income | $27.0M | $3.2M | $3.3M | -$969.0K |
| Net margin | 14.1% | 1.6% | 1.8% | −0.6% |
| Diluted EPS | $0.74 | $0.09 | $0.13 | $-0.12 |
| EBITDA | $39.2M | $35.2M | $31.7M | -$58.5M |
| Operating cash flow | $35.2M | $45.2M | $26.9M | -$9.2M |
| Free cash flow | $28.3M | $38.3M | $24.2M | -$11.0M |
| Diluted shares | 36.7M | 34.3M | 25.7M | 8.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $24.1M | $39.3M | $89.0M | $79.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $107.0M | $107.4M | $112.9M | $118.3M |
| Total assets | $107.6M | $122.4M | $155.3M | $111.6M |
| Total liabilities | $158.0M | $224.6M | $191.8M | $165.8M |
| Shareholders' equity | -$50.4M | -$102.2M | -$36.5M | -$54.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology